Need for a clinical trial on post-traumatic stress in the Armed Forces of Colombia

Need for a clinical trial on post-traumatic stress in the Armed Forces of Colombia

According to the USA National PTSD Center, more than 8% of the US population suffers from post-traumatic stress disorder.


A study published by the British Journal of Psychiatry, by the authors: Dückers ML, Alisic E, Brewin CR. mentions that Canada has some of the highest rates of PTSD, with an estimated 9.4% of the population experiencing some form of the disease.


In Israel, a country where military service and reserve duty is mandatory, post-traumatic stress disorder is frequent. In Israel, approximately 9.4% of citizens have been diagnosed with post-traumatic stress disorder, according to the study by Bleich et al. (2003).

A country like Colombia with more than 50 years of conflict and wars with mafias, drug traffickers, paramilitaries, guerrillas with confrontations, massacres, terrorist attacks that have left more than 8 million dead (almost 20% of the population).


In Colombia, the PTSD indicator is not known according to the researcher Vallejo (2009, 2011), but some clues indicate that the figure may be significantly higher than countries such as the United States, Canada and Israel.


Thus, it is essential to motivate and promote a study of the effectiveness of medical cannabis in post-traumatic stress in Colombia, starting with its military forces.


How is it possible that Israel, Canada and the United States have studies on Post-Traumatic Stress in their Armed Forces and Colombia, with all the violence they have suffered, with all the evidence that shows that it is not a peaceful country, with all the facilities that exist today to investigate the efficacy of Medicinal Cannabis in Colombia, from the law passed in August 2016 by the Colombian Congress that regulates the medicinal use of cannabis, we do not have a clinical trial that allows us to face this serious illness that affects to a greater extent the members of the Armed Forces and in general to almost the entire population.


Post-traumatic Stress in the armed forces

Post-traumatic Stress in the armed forces

Anyone, regardless of their age or circumstance, who has experienced a traumatic event may be susceptible to PTSD (Post Traumatic Stress Disorder – the inability of some people to extinguish traumatic memories).


After a traumatic event, patients with PTSD are likely to feel feelings and thoughts related to the trauma, experience nightmares, memories, emotional distress, and hypervigilance among a host of other symptoms.


Post-traumatic stress is mainly due to fear learned. When you have more fear learned, that will induce a state of hypervigilance and that can also cause nightmares and terrors at night. This learned fear makes it difficult to modulate feelings and reactions, especially with respect to situations that trigger memory or trauma experience.


The extinction of memory occurs naturally, organically in the average population. However, some people who have experienced a trauma or traumatic event have an impairment to their natural capacity for memory extinction.


According to the US National Center for PTSD UU., More than 8% of the US population. UU suffers from post-traumatic stress disorder, 26% of which are men and women of military service. In Israel, approximately 9% of citizens have been diagnosed with post-traumatic stress disorder, a country where military service and reserve duty is mandatory, and who have generally lived in permanent war, post-traumatic stress disorder It is frequent. Canada has some of the highest rates of PTSD, with an estimated 9.4 percent of the population experiencing some form of the disease


Conventional treatments against PTSD include powerful sedatives, antidepressants, anti-anxiety drugs and, in extreme cases, antipsychotics. Most of these medications are based on opioids, which can cause a variety of devastating side effects (restlessness, anxiety) and long-term problems (tachycardia, addiction, and suicidal tendencies). This has led to an epidemic of opioids, which has led to a considerable increase in deaths.


This has become in these countries a problem that has demanded attention and answers aimed at solving it in a different way.


Medical cannabis has been shown to support the extinction capabilities of the body’s endogenous memory, reducing the ability of traumatic memories to trigger the symptoms of PTSD.


Cannabis is a much better and safer and more effective alternative. Because of its antisuppressive, anti-stress and anti-depressant properties, it also allows reducing the deficiency of Anandamide, common in patients with PTSD.


The most advanced countries in the application of medical cannabis in PTSD are: United States, where the Dr. Sue Sisley is internationally recognized expert, in Canada is Dr. Mike Hart who along with movements such as Marijuana for Trauma ( have become standard bearers of the TEP, in Israel are Dr. Irit Akirav of the University of Haifa, and Dr. Yasmin Hurd, and movements such as: Lochamim Lchaim – Fighting for Life (


Dr. Sue Sisley is the Principal Investigator of the only FDA-approved randomized controlled trial in the world that examines the safety and efficacy of medical cannabis in combat veterans with treatment-resistant post-traumatic stress disorder. The study is the largest awarded by the Department of Public Health and Environment CDPHE Colorado (US $ 2.1M)


Veterans represent 20% of national suicide rate, this translates into 22 veterans who commit suicide every day, in three years the number of veterans who have committed suicide totals 24,000. These veterans correspond to those resistant to the treatment of PTSD.


Patients with PTSD suffer a comorbidity rate, which means that they experience more than one condition at a time. 79% of women and 88% of men diagnosed with PTSD also suffer from depression, substance abuse and anxiety disorders. Given the growing evidence that cannabis is a treatment for depression, anxiety and substance abuse, the potential benefit of cannabis treatment for comorbidity is very promising. This, combined with a growing body of evidence that the endocannabinoid system has a role in reducing fear and anxiety, suggests that cannabinoids can also have positive effects in reducing suicidal thoughts and behaviors.


There is great potential for medical cannabis to become a multi-therapy, rather than having to take as many different medications for all the symptoms and parallel conditions as monotherapy.